Luca Piccoli

Proud to be part of this collective effort with incredible colleagues at many hospital systems and universities across Switzerland, Italy and the U.S. to further our understanding of COVID-19 and help improve public health.

Excited to share @iScience_CP published our research on #COVID19 mRNA vaccines! Data show these vaccines elicited memory B cells that became better at targeting #SARSCoV2 variants over time, possibly extending vaccine protection. Check it out: tinyurl.com/yabrt84n #TeamVir

#BREAKING: In partnership with @GSK, we're thrilled to share breaking news about the COMET-ICE trial evaluating our investigational monoclonal antibody for #COVID19. The IDMC recommended the study stop enrollment early given demonstration of efficacy. bit.ly/comet-ice

🔬🦠 #Ricerca su #COVID19: da un progetto collaborativo #IRB, @EnteOspedaliero, #ClinicaLuganeseMoncucco e #Humabs nuove prospettive sulla risposta anticorpale al #coronavirus #SARSCoV2. Lo studio pubblicato su #Cell. #ricercascientifica #immunologia usi.ch/it/feeds/14467

New research by Vir scientists characterizing antibody response to #COVID19 was published in @CellCellPress. Read more: bit.ly/cellpub

Our paper is the top story in human immunology news! #natalizumab #MultipleSclerosis #immunogenicity #deimmunization #antidrugantibodies #tcell #abirisk app.e.stemcell.com/e/es.aspx?s=18…

Check it out our approach to identify weak spots of therapeutic antibodies, and to minimize their immunogenicity #MultipleSclerosis #therapeutic #antibodies #rational #design #immunology #Tcells @USI_university nature.com/articles/s4159…